## Mary Geitona

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11071708/publications.pdf

Version: 2024-02-01

933447 839539 22 345 10 18 citations g-index h-index papers 23 23 23 515 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Self-Rated Health: Inequalities and Potential Determinants. International Journal of Environmental Research and Public Health, 2009, 6, 2456-2469.	2.6	68
2	The cost of COPD exacerbations: A university hospital $\hat{a} \in$ based study in Greece. Respiratory Medicine, 2011, 105, 402-409.	2.9	44
3	Determinants of healthcare utilization in Greece: Implications for decision-making. European Journal of General Practice, 2007, 13, 144-150.	2.0	40
4	A systematic review of cost–effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives. Pharmacogenomics, 2010, 11, 989-1002.	1.3	26
5	Generics market in Greece: The pharmaceutical industry's beliefs. Health Policy, 2006, 79, 35-48.	3.0	21
6	Cost–effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs. Pharmacogenomics, 2012, 13, 1405-1417.	1.3	17
7	Health status and access to health services of female prisoners in Greece: a cross-sectional survey. BMC Health Services Research, 2016, 16, 243.	2.2	17
8	Cost estimation of patients admitted to the intensive care unit: a case study of the Teaching University Hospital of Thessaly. Journal of Medical Economics, 2010, 13, 179-184.	2.1	16
9	The annual direct costs of stable COPD in Greece. International Journal of COPD, 2018, Volume 13, 309-315.	2.3	13
10	Comparative Analysis of Legislative Requirements About Patients' Access to Biotechnological Drugs for Rare Diseases in Central and Eastern European Countries. Frontiers in Pharmacology, 2018, 9, 795.	3.5	13
11	Professional Quality of Life and Occupational Stress in Healthcare Professionals During the COVID-19 Pandemic in Greece. Health Services Insights, 2022, 15, 117863292210960.	1.3	13
12	The economic burden of treating neonates in Intensive Care Units (ICUs) in Greece. Cost Effectiveness and Resource Allocation, 2007, 5, 9.	1.5	10
13	Medication use and patient satisfaction: a population-based survey. Family Practice, 2008, 25, 362-369.	1.9	10
14	Cost analysis and estimation of thoracic surgical patients with lung cancer in Greece: the case of Sotiria ICU. Intensive and Critical Care Nursing, 2001, 17, 322-330.	2.9	8
15	Colocteral cancer management and prevention policies in Greece. European Journal of Health Economics, 2010, 10, 27-33.	2.8	6
16	Budget impact analysis on erythropoiesis–stimulating agents use for the management of chemotherapy-induced anaemia in Greece. Cost Effectiveness and Resource Allocation, 2013, 11, 16.	1.5	6
17	Health Systems' Challenges and Responses for Recovery in the Pre and Post COVID-19 Era. Journal of Service Science and Management, 2021, 14, 444-460.	0.5	6
18	The pharmacological cost of COPD during Greek economic crisis. International Journal of COPD, 2017, Volume 12, 461-466.	2.3	5

#	Article	IF	CITATIONS
19	Cost estimation of neonatal intensive care in Greece: the case of Athens maternity hospitals. Journal of Medical Economics, 2007, 10, 273-283.	2.1	2
20	Assessment of the Mobile Mental Health Units' effectiveness in Cyclades islands. Psychiatrikē = Psychiatriki, 2021, 32, 199-207.	0.6	2
21	Detection and Reporting of Adverse Drug Reactions Related to Antibiotics in Primary Healthcare in Greece. Current Drug Safety, 2022, 17, 217-224.	0.6	1
22	Cost-minimisation analysis of oral anticoagulant therapy monitoring methods: the case for prothrombin time self-monitoring. Hellenic Journal of Cardiology, 2008, 49, 388-96.	1.0	0